Mereo BioPharma (MREO) Short term Debt (2017 - 2023)

Mereo BioPharma (MREO) has reported Short term Debt for 6 consecutive years, with $5.2 million the latest figure, recorded in Q2 2023.

• Quarterly Short term Debt fell 73.92% year-over-year to $5.2 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $5.2 million (down 73.92% YoY) and the FY2022 annual result came in at $13.0 million, changed N/A from the prior year.
• Short term Debt eased to $5.2 million in Q2 2023 per MREO's latest filing, from $13.0 million in the prior quarter.
• Over the last five years, Short term Debt for MREO reached as high as $20.1 million in Q2 2022 and fell as low as $5.2 million in Q2 2023.
• A 4-year average of $14.1 million and a median of $14.7 million in 2020 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2019 — Short term Debt jumped 121.22% — and 2023, when it tumbled 73.92%.
• Year by year, Short term Debt stood at $19.5 million in 2019, then retreated by 15.45% to $16.5 million in 2020, then fell by 21.0% to $13.0 million in 2022, then plunged by 59.71% to $5.2 million in 2023.
• According to Business Quant data, Short term Debt over the past three periods registered $5.2 million, $13.0 million, and $20.1 million for Q2 2023, Q4 2022, and Q2 2022 respectively.